RE:RE:RE:RE:The Longest Day Yeah Doc, I'm with ya here too. If for some odd reason things get really stalled in Canada, a high % of the first 12 at 1 yr CR would still get their attention, especially if it is only off of a single treatmet. I don't expect that to happen, I actually think things will begin to get back to normal once we get the hot summer weather.
Hempdoc wrote:
Based on the typical summer slumber for respiratory viruses & more hospitals being opened for business, it shouldn't be too difficult to get 20 patients treated by end of fall (especially if the US is on board)...& just before the typical late fall/winter wave of resp. viruses.
Any long term run needs confirmatory data. Canadian data helps, but opening those American doors can pretty much guarantee a doubling or tripling of our current pace = significantly faster path to statistical significance. That IND approval thus carries a lot of weight/value based on anticipated results (at least in our eyes). But a "sustained run" on this exchange without accompanying solid 6 month/1 yr data in more than "a few" patients...not likely going to happen imo....maybe get a bump up to $0.40. Ultimately, the IND approval is only as good as the data it enables & where it's enabled. I believe once we get solid confirmatory American data (my guess...at least 6 to 10 patients), we will have more than enough reason to celebrate in Vegas. However, 10 to 12/12 Canadian with IND in hand should get us past Barstow....JMO. Good luck...